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A B S T R A C T
The rise of widespread antifungal resistance fuels the need to explore new classes of inhibitory molecules as
potential novel inhibitors. Recently a plant natural product poacic acid (PA) was shown to inhibit β-1,3-glucan
synthesis, and to have antifungal activity against a range of plant pathogens and against Saccharomyces cerevi-
siae. As with the echinocandins, such as caspofungin, PA targets the synthesis of cell wall β-1,3-glucan and has
potential utility in the treatment of medically important fungi. However, the antifungal activity of PA against
human pathogenic Candida species has not been explored and the precise mode of action of this compound is not
understood. Here, we show that PA sensitivity is regulated by the calcineurin pathway and that susceptibility to
PA varied significantly between Candida species, but did not correlate with in vitro β-glucan synthase activity,
cell wall β-glucan content or the sensitivity of the species to caspofungin. Strains with point mutations (S645Y or
S645P) in the hotspot1 region of the β-1,3-glucan synthase subunit Fks1, had decreased sensitivity to caspo-
fungin but increased sensitivity to PA. C. guilliermondii, C. orthopsilosis, and C. parapsilosis were more sensitive to
PA than C. albicans, C. dubliniensis, C. tropicalis, and C. glabrata. These observations suggest that there are sig-
nificant differences in the mode of action of PA and caspofungin and that PA or PA analogues are not likely to
have broad spectrum activity in the treatment of Candida infections.
Introduction
The fungal cell wall is a dynamic organelle that is essential for its
viability. The fungal cell wall is a promising antifungal target for the
therapeutic treatment of human fungal pathogens because the major
components - chitin, glucan, and mannan, are absent from the human
body. Depending on the fungus and growth conditions, the proportion
and structural composition of cell wall components varies considerably
(Free, 2013; Erwig et al., 2016; Gow et al., 2016; Gow et al., 2017).
However, to date all fungi examined have β-1,3-glucan in their cell wall
and this plays critical roles as a physical barrier, as a scaffold for the
attachment of other cell wall components and in maintaining cell shape
(Gow et al., 2017). This makes β-1,3-glucan synthesis an ideal broad-
spectrum target for antifungal drugs. However, the cell wall is dynamic
and can alter its structure depending on the environment and carbon
source the fungi encounter, and in response to cell wall stress. Activa-
tion of the Ca2+/calcineurin, HOG and PKC pathways all occur in re-
sponse to cell wall damage and result in the induction of compensatory
mechanisms such as the synthesis of chitin (Munro et al., 2007; Munro,
2013; Gow et al., 2017). Failure to maintain cell wall integrity com-
promises cell viability and ultimately results in cell death (Negishi
et al., 2010; Rodríguez-Pena et al., 2010; Walker et al., 2013a,b),
therefore, cell wall integrity is constantly monitored via sensors located
in the cell wall and membrane and at critical cell cycle check points
(Roberts et al., 1983; Suzuki et al., 2004; Côte et al., 2009; Negishi
et al., 2010; Gow et al., 2012; Negishi et al., 2016).
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The three echinocandins caspofungin (CSF), micafungin, and ani-
dulafungin, are the newest class of antifungal agents on the market and
have been clinically approved by the US Food and Drug Administration
since 2001 (Pappas et al., 2009; Pound et al., 2010; Pfaller, 2012;
Perlin, 2015b). They are non-competitive inhibitors of β-1,3-glucan
synthase (Douglas et al., 1997; Odds, 2010; Nett et al., 2016) and
therefore are not substrate analogues that bind to the enzyme active
site. Indeed, the physical binding site of echinocandins to the Fks1
target protein has not been precisely defined. A number of clinical cases
of echinocandin resistance have been reported (Imtiaz et al., 2012;
Arendrup et al., 2014; Perlin, 2015b; Sanglard, 2016) which is most
commonly due to amino acid substitutions in Fks1, one of three major
“hotspots” regions in the predicted external face of the β-1,3-glucan
synthase transmembrane protein (Kurtz et al., 1996; Park et al., 2005;
Garcia-Effron et al., 2008; Garcia-Effron et al., 2009a; Johnson et al.,
2011; Johnson and Edlind, 2012; Perlin, 2015b; Kolaczkowska et al.,
2016; Prasad et al., 2016). For example, in C. albicans the serine645 to
proline or tyrosine amino acid substitution at of Fks1 is frequently
found in echinocandin-resistant strains (Perlin, 2015a; Perlin, 2015b).
These mutations are often, but not always, accompanied by elevated
cell wall chitin content (Ben-Ami et al., 2011; Ben-Ami et al., 2012; Lee
et al., 2012; Perlin, 2015a, 2015b Perlin et al. 2015; Walker et al.,
2013a,b). However, resistance to CSF has also been described which is
not associated with amino acid substitutions in Fks1. In addition, C.
albicans strains that have an elevated chitin content in the cell wall are
significantly less susceptible to CSF in vivo and in vitro (Walker et al.,
2008; Lee et al., 2012; Walker et al., 2015). Paradoxical growth (also
called the “Eagle effect”) of C. albicans at which growth still occurs at
supra-MIC concentrations of the echinocandins has also been shown to
be correlated with up-regulation of chitin synthesis (Stevens et al.,
2006; Stevens, 2009). Furthermore, a number of CSF resistant isolates
are found in other “non-albicans” species (Garcia-Effron et al., 2010;
Perlin, 2011; Perlin, 2015b), including the emerging pathogen Candida
auris, where as many as one third of strains are echinocandin resistant
or cross-resistant (Lockhart et al., 2017a,b). These health challenges
highlight the need for new antifungal agents to augment the antifungal
armamentarium.
Poacic acid (diferulate, 8-5-DC), PA, is a natural plant metabolite
found in the lignocellulosic hydrolysates of grasses and has been
characterised as a promising antifungal agent that targets β-1,3-glucan
synthesis (Piotrowski et al., 2015). This compound inhibited growth of
Saccharomyces cerevisiae, Alternaria solani and the oomycete Sclerotinia
sclerotiorum in vitro. Lesion development on soybean leaves by S.
sclerotiorum was also inhibited by PA ex vivo. PA apparently acts by
directly binding to β-1,3-glucan polysaccharide, and therefore differs
from the mode of action of echinocandins which directly target the β-
1,3-glucan synthase enzyme. In this study we contrast the modes of
action of two β-glucan synthesis inhibitors, poacic acid (PA) and cas-
pofungin and show that they have distinct mode of actions and different
host range activities. We determined the activity of PA against a range
of clinically important fungal pathogens and demonstrate that PA is
differentially active against a range of Candida species and examine the
relationship between species-specificity, β-1,3-glucan synthesis and its
sensitivity to PA. Our findings demonstrate that PA and echinocandins
inhibit β-1,3-glucan synthesis in different ways and that PA-based
pharmacophores may not be suitable as pan-Candida inhibitors.
Results
Differential sensitivity of C. albicans and S. cerevisiae to PA. First we
investigated the antifungal activity of PA against the C. albicans re-
ference strain SC5314, and S. cerevisiae S288C (shown previously to be
sensitive to PA) as well as the echinocandin resistant C. albicans NR3
strain. As shown in Fig. 1A, S. cerevisiae was 5- to 10-fold more sensitive
(inhibitory concentration, IC50= 110 µg/ml) to PA than both C. albi-
cans strains, NR3 (IC50= 515 µg/ml) and SC5314 (IC50 > 1000 µg/
ml). The measured sensitivity against S. cerevisiae corresponds with that
cited previously (Piotrowski et al., 2015). Therefore C. albicans SC5314
was significantly less sensitive to PA despite being echinocandin sen-
sitive (Fig. 1C). Unexpectedly, the CSF resistant C. albicans NR3 strain
was significantly more sensitive to PA, than SC5314. When the cells
from the MIC assays were re-plated on YPD agar plates in the absence of
drug the PA-treated C. albicans SC5314 and NR3 strains grew normally,
demonstrating that PA had a fungistatic, rather than a fungicidal effect
on growth (Fig. 1B and D).
Kinetic analyses revealed a correlation between the inhibition of β-
1,3-glucan synthase enzyme activity and echinocandin MIC (Garcia-
Effron et al., 2009b). In addition, S. cerevisiae β-1,3-glucan synthase
activity was reduced when treated with PA and 14C-glucose in-
corporation in glucan was significantly decreased (Piotrowski et al.,
2015). Therefore, we compared the effect of PA on β-glucan synthase
activity using microsomal cell membrane preparations as a source of
Fks1 enzyme. The inhibitory concentration (IC50GS) was determined for
β-1,3-glucan synthases isolated from the total membrane fractions in
SC5314, NR3, and S288C. The glucan synthase activity of all three
stains was found to be inhibited to a similar extent by PA (Fig. 1E). The
PA IC50GS for β-1,3-glucan synthase of SC5314 was 194 µg/ml, which
was comparable to NR3 (IC50GS= 220 μg/ml) and S288C
(IC50GS= 206 μg/ml) suggesting that this hotspot mutation that confers
echinocandin resistance is irrelevant for PA sensitivity. Therefore, in in
vitro assays, PA inhibited C. albicans and S. cerevisiae β-1,3-glucan
synthases to the same degree suggesting that the differential sensitivity
of the C. albicans and S. cerevisiae is not due to differences in the direct
action of PA on Fks1 activity.
Combinatorial synergy between PA and cell wall synthesis in-
hibitors. PA could potentially be useful as part of a combinatorial
therapy against Candida infections. Piotrowski et al. demonstrated that
PA and CSF acted synergistically against S. cerevisiae (Piotrowski et al.,
2015). Therefore, we carried out sensitivity assays using combinations
of PA and CSF against C. albicans. The results described indicate com-
bination of PA and CSF only had a noticeable inhibitory effect the
growth of both C. albicans and S. cerevisiae, compared to treatment with
each inhibitor alone (Fig. 2A). Noticeably, when C. albicans SC5314 was
treated solely with CSF, it displayed paradoxical growth at> 8 μg/ml
(Fig. 2A). This paradoxical growth was abolished when SC5314 was
treated with both PA and CSF. Combinatorial effects calculated using
the sub-MIC/IC50 values of PA and CSF, indicated mild synergist effects
of additions of PA and CSF for the NR3 CSF resistant strain and S.
cerevisiae S288C (Fig. 2B). However, combinatorial treatments of PA
and two other echinocandins, micafungin and anidulafungin, did not
demonstrate synergistic inhibition against the C. albicans wild type
strain (data not shown).
Because chitin synthesis protects cells from β-glucan damage we
also tested potential synergies between PA and chitin synthesis in-
hibitors nikkomycin Z (NKZ) (a competitive inhibitor of chitin syn-
thase) and CFW (which can have a cidal effect against fungi by binding
to nascent chitin and disrupting chitin chain maturation) (Roncero
et al., 1985; Gaughran et al., 1994). Similar to previous findings with S.
cerevisiae (Piotrowski et al., 2015), we observed that PA and NKZ
showed no synergistic effect against C. albicans (Fig. 2C). However, C.
albicans SC5314 treated with both PA and CFW exhibited a synergistic
effect on growth (Fig. 2C). These results indicate that the combination
of PA and CFW may enhance the cell wall polysaccharide instability,
leading to enhanced killing.
PA has no effect on chitin content of the C. albicans wild type cell
wall. In fungi, β-glucan damage often leads to the induction of chitin
synthesis (Munro et al., 2007; Walker et al., 2008; Lee et al., 2012).
Therefore, we assessed the effect of PA on cell wall chitin measured by
staining cells with CFW. DMSO treated cells of all three stains tested
had no significant effect on chitin stimulation compared to the un-
treated controls. For wild type C. albicans, CSF treatments stimulated
chitin synthesis, but PA did not (Fig. 3A and B). However, for the CSF
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resistant C. albicans NR3 mutant both PA and CSF stimulated chitin
deposition or contents. Although microscopic observations suggested
that the pattern of chitin upregulation between NR3 and S. cerevisiae
were not identical, both PA and CSF stimulated chitin synthesis in S.
cerevisiae (Fig. 3A and B). These data suggest that both PA and CSF
compromised cell wall integrity.
Next we investigated whether the PKC/Mkc1 pathway that results in
enhanced chitin formation was activated by PA (Fig. 3C). As expected,
CSF treatment resulted in activation of Mkc1p/Mpk1p in both C. albi-
cans and S. cerevisiae. Mkc1 phosphorylation was less in NR3 induced
compared to SC5314 or S288C when cells were treated with CSF. PA
activated Mpk1 phosphorylation in S288C, reflecting its ability to sti-
mulate chitin synthesis in this species (Fig. 3A and B). There was no
significant stimulation of Mkc1 phosphorylation in C. albicans SC5314
treated with PA (Fig. 3C). Therefore chitin stimulation by PA may be
mediated by alternative cell wall integrity pathways.
PA does not affect glucan and mannan content of C. albicans. The
impact of PA on glucan and mannan content was determined by
fluorescence microscopy using Aniline Blue and Alexa-ConA, to stain β-
1,3-glucan and mannan respectively. In controls, treatment of S. cere-
visiae with PA and echinocandin B significantly decreased β-1,3-glucan
staining in buds (Fig. 4A and B). Since de novo synthesis of β-1,3-glucan
occurs at sites of budding, the reduced staining in buds implies im-
pairment of β-1,3-glucan synthesis after drug treatment (Piotrowski
et al., 2015). In contrast, PA did not alter mannan staining (Fig. 4A and
B), confirming the fact that PA acts primarily on the formation of β-1,3-
glucan in S. cerevisiae (Piotrowski et al., 2015). PA also decreased β-1,3-
glucan staining in C. albicans buds (Fig. 4A), but this was not statisti-
cally significant at p > 0.05 (Fig. 4B). The echinocandin-resistant NR3
strain was unaffected by echinocandin B, but the synthesis of β-glucan
Fig. 1. PA sensitivity and glucan synthase activity of C. albicans. Sensitivity of C. albicans SC5314 (wild type), NR3 (containing a point mutation in FKS1) and S.
cerevisiae S288C to PA [A] and caspofungin [C]. Samples of 2.5 μl from the wells of the MIC plates were spotted on YPD plates and incubated at 30 °C for 24 h [B & D].
Error bars are SEM (n= 3). [E] Membranes of SC5314, NR3, and S288C were prepared from logarithmic-phase cells and glucan synthase (GS) activities were
measured after solubilization of purified membrane with 0.4% Brij-35. Final concentrations of PA were 8, 16, 32, 64, 128, 256, and 512 μg/mL. All measurements
were performed in triplicate. Plots of S288C, SC5314, and NR3 separately show mean values ± SD (n= 3). The half maximal inhibitory concentration (IC50GS) of
S288C, SC5314 and NR3 were 206, 194 and 220 µg/ml, respectively.
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of buds was slightly affected by PA (Fig. 4B). Neither PA nor echino-
candin B significantly affected mannan synthesis in either S. cerevisiae
or C. albicans. Reinforcing this, HFP-TEM images did not reveal any
gross changes in the outer (mannan) and inner (glucan+ chitin) layers
of S. cerevisiae and C. albicans cell walls after PA treatment (Fig. 4C-D).
The calcineurin pathway influences sensitivity to PA. Previous stu-
dies have demonstrated that the Ca2+/calcineurin pathway is im-
portant for the cell remodelling and chitin upregulation of C. albicans in
response to Ca2+, CFW, or/and caspofungin (Munro et al., 2007;
Walker et al., 2008; Lenardon et al., 2009). To further investigate
whether PA effected cell wall remodelling and integrity, a number of C.
albicans mutants, that were defective in cell wall synthesis or cell wall
integrity pathways were tested for their sensitivity to PA (the strains
used are listed in Suppl. Table 1). Four groups of selected mutants were
examined: 1) strains lacking genes involved in cell wall integrity
pathway genes (MKC1, CEK1, CNA1, and CNB1) (Navarro-Garcia et al.,
1995; Csank et al., 1998; Cruz et al., 2002; Sanglard et al., 2003), 2)
mutants in cell wall chitin synthase genes (CHS3, CHS2, and CHS8)
(Bulawa et al., 1995; Mio et al., 1996; Munro et al., 2003), 3) man-
nosylation mutants (OCH1, PMR1, MNN2 family, MNN4, MNT1, MNT2,
Fig. 2. Combinatorial treatment of caspofungin and PA against C. albicans. [A] Sensitivity assays combining PA and caspofungin (CSF) were carried out according to
CLSI methodology. Optical densities were measured after 24 h. The heat map is based on the average of three individual values expressed as percentage growth. [B]
Growth inhibition due to PA in combination with CSF at sub-MIC concentration calculated as described in the Materials and Methods and presented as percentage
growth compared to untreated controls. [C] Inhibition of growth in the presence of PA with or without supplementation with chitin synthesis inhibitors (CHSi) – CFW
or nikkomycin Z (NKZ). E=expected percentage growth when both compounds are applied (See Materials and Methods). *p < 0.05 (n= 3) compared to the DMSO
control.
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and MNS1) (Hobson et al., 2004; Bates et al., 2005; Munro et al., 2005;
Bates et al., 2006; Mora-Montes et al., 2007; Hall et al., 2013), and 4)
mutants in genes encoding glucan synthase, glucosidase, or glucosyl-
transferase (PHR1, PHR2, CWH41, SMI1, KRE62, C1_14060W, XOG1,
PGA4 and PGA5) (Fonzi, 1999; Noble et al., 2010). PA sensitivity tests
were performed according to the CLSI methods (see Materials and
Methods). The phr1Δ mutant was grown in NGY broth at pH 5 and
inoculated in RPMI-1640 at pH 5 for MIC tests. Cells lacking either
CWH41 or PHR1 showed growth defects in unstimulated conditions,
and were not used for PA susceptibility testing. Only cna1Δ and cnb1Δ
exhibited significantly increased sensitivity to PA (Fig. 5A). The IC50
values of cna1Δ and cnb1Δ were 332 μg/ml and 430 μg/ml, respectively
representing a 3-fold and 2.4-fold increase in susceptibility to PA. None
of the other mutants tested had significantly altered sensitivities to PA
(Suppl. Fig. 1). Therefore, the calcineurin pathway is involved in PA
tolerance in C. albicans.
Point mutations in Fks1 affecting PA sensitivity. The sensitivity to
CSF can be decreased by amino acid substitutions in the Fks1 hotspot
regions (Ben-Ami et al., 2011; Ben-Ami et al., 2012). We tested several
clinical isolates and laboratory derived strains containing point muta-
tions in Fks1 Hotspot 1 for their sensitivity to PA (Table 1). The la-
boratory derived strains, fks1-S645S/P (a heterozygous mutant) and
fks1-S645P (a homozygous mutation at 645 serine to proline), were
generated using CRISPR-CAS9 to introduce this point mutation (see
Materials and Methods). A heterozygous FKS1/fks1Δ null mutant was
compared displaying marginally reduced sensitivity to PA and in-
creased sensitivity to CSF (Fig. 5B; Table 1). A variety of point muta-
tions in Fks1 result in elevated susceptibility to PA. Particularly strains
including NR3 (S645Y), DPL1008 (S645P), and fks1-S645P all had
significantly increased susceptibility to PA (Fig. 5B), with IC50s of
515 μg/ml, 767 μg/ml, and 590 μg/ml, respectively (Fig. 5B; Table 1).
Amino acid substitutions in Fks1 at 641 (DPL12), 648 (DPL1012), or
689 (DPL1013) did not result in significantly altered PA sensitivity
relative to the wild type control (Fig. 5B). Therefore, a variety of point
mutations in Fks1 result in elevated susceptibility to PA.
Sensitivity of PA against various Candida species. We next in-
vestigated PA susceptibility against 10 different Candida species (63
strains) and four strains of S. cerevisiae (S288C, AM2001/0017, M2375/
94/7, and AM13/001) (Fig. 6; Suppl. Table 1). The S. cerevisiae strains
were most sensitive to PA. C. krusei, C. parapsilosis, and C. orthopsilosis
were more sensitive to PA compared to C. albicans (Fig. 6). Compared to
those Candida species, C. guilliermondii showed the most variable PA
sensitivity. For example, the C. guilliermondii strains ATCC 6260, 81/
054, and SCS192139L were relatively susceptible to PA (IC50= 10 to
430 μg/ml), whereas M476/93/6, SCS192139P, AM2005/0181, and
AM2005/0052 were somewhat less sensitive to PA (IC50= 616 to >
1000 μg/ml). This species is also variable in its sensitivity to CSF
(Walker et al., 2013a,b). Interestingly, C. glabrata was relatively less
sensitive to PA compared to S. cerevisiae despite of phylogenetical si-
milarity between two species. Furthermore, C. albicans, C. dubliniensis,
and C. tropicalis were relatively less sensitive to PA compared to S.
cerevisiae. Of the more uncommon Candida species, C. lusitaniae and C.
auris were generally less sensitive to PA. Therefore, PA sensitivity was
both species- and strain-dependent.
β-glucan content does not correlate with the sensitivity of PA to
different Candida species. PA has been reported to bind directly to β-
1,3-glucan (Piotrowski et al., 2015). We therefore investigated whether
exogenous β-1,3-glucan could influence PA sensitivity (Fig. 7A). As a
control, C. albicans and S. cerevisiae were grown in the medium only
with exogenous β-1,3-glucan at 0.5 mg/ml. Under these growth con-
ditions, the presence of exogenous β-1,3-glucan (0.5mg/ml) did not
impact cell growth of either C. albicans and S. cerevisiae (data not
shown). In C. albicans the PA sensitivity was hardly affected by exo-
genous β-1,3-glucan at 0.25mg/ml and 0.5mg/ml (Fig. 7Ai). On the
Fig. 3. Chitin content of C. albicans treated with PA.
[A] Cell wall chitin contents of C. albicans SC5314,
NR3 and S. cerevisiae S288C treated with either PA or
caspofungin (CSF). C. albicans and S. cerevisiae cells
were treated with 0.5mg/ml and 0.1mg/ml PA, re-
spectively and with 32 ng/ml CSF at 30 °C for 6 h.
After treatment, cells were fixed and stained with
25 µg/ml CFW. Scale bars are 10 μm. [B] The fluor-
escent intensity was measured and expressed as per-
centage of control values (SC5314, no treatment,
none). * p < 0.05. ** p < 0.001, *** p < 0.0001.
Error bars= SEM (n > 50). [C] Western blot ana-
lysis of phospho-Mkc1p of C. albicans SC5314 and
NR3, and phospho-Mpk1p in S. cerevisiae S288C
treated with DMSO, PA, and CSF. Cells were grown at
30 °C for 4 h and treated with drugs for 10min.
Proteins were extracted and same amount of protein
were loaded per lane. (None= no treatment; DMSO,
0.5% DMSO; PA, 0.5mg/ml PA; CSF, 32 ng/ml CSF).
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other hand, the growth of S. cerevisiae was ameliorated by addition of
exogenous β-1,3-glucan in a dose-dependent manner (Fig. 7Aii).
Therefore, the sensitivity of S. cerevisiae to PA was influenced by exo-
genous β-1,3-glucan in a PA-concentration-dependent manner
(Fig. 7Aii).
Next we hypothesized that varied basal levels of glucan in different
Candida species may influence PA sensitivity. To test this, the β-1,3-
glucan content in Candida cells was quantified using Aniline Blue
staining by FACS (Fig. 7B). C. albicans NR3 had the highest glucan
content and C. guilliermondii ATCC 6260 had the lowest among the
strains tested, and the corresponding IC50 values of these strains were
515 μg/ml and 430 μg/ml. Additionally, the glucan contents of C. al-
bicans wild type (SC5314) and S. cerevisiae S288C were comparable, but
the IC50 values were 111 μg/ml and > 1000 μg/ml, respectively.
Therefore, the PA sensitivity did not correlate simply with the basal β-
1,3-glucan content of the cell wall of different yeast species.
Correlation between computational prediction of β-1,3-glucan to-
pology and PA sensitivity. The predicted transmembrane domains of C.
albicans Fks1 were highly conserved in C. dubliniensis and C. tropicalis
Fks1 but different in S. cerevisiae Fks1 and C. glabrata Fks1 (Suppl.
Figs. 2 and 3). We noted a significant correlation between PA sensitivity
and Fks1 active domain topology of five species (C. albicans, C. du-
bliniensis, C. tropicalis, C. glabrata, C. krusei, and S. cerevisiae (p < 0.05
according to Fisher’s exact test; Suppl. Table 3). One Fks1 domain was
predicted to be located on the cytosolic face of the membrane for the
most PA sensitive species - C. guilliermondii, C. parapsilosis, C.
Fig. 4. Effect on PA on mannan and glucan in S. cerevisiae and C. albicans. [A] Cells were treated with PA (PA) or echinocandin B (EB), and stained with either Aniline
Blue to visualise glucan or Alexa-ConA to stain mannan. S288C and SC5314 cells were treated with 500 µg/mL PA. NR3 cells were treated with 125 µg/mL PA at 30 °C
for 6 h. The three strains were treated with 4 µg/mL echinocandin B at 30 °C for 2 h. Scale bars represent 5 μm. [B] Semi-quantification of fluorescence intensity of
Aniline Blue and Alexa-ConA with or without PA or echinocandin B. “Equal” represents cells where both mother and daughter cells stained uniformly. “Bud”
represents cells with strong staining on daughter cells. “Mother” represents heavy staining of mother cells. Data are percentages of three independent groups.
(n > 3). [C and D] C. albicans wild type (SC5314) and S. cerevisiae (S288C) cells were treated with PA 0.5 μg/ml or 0.1 μg/ml, respectively for 6 h. Scale
bars= 500 nm. The thickness of the inner cell wall (chitin and glucan layer) and outer cell wall (mannoprotein fibrils only) was quantified as described in the
Materials and Methods. Mean ± SD (n > 8).
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orthopsilosis, and S. cerevisiae) (Suppl. Fig. 3). However, the topology
and function of this domain has yet to be examined experimentally.
Discussion
The natural plant metabolite PA has been shown to have antifungal
and anti-oomycete activity for a range of plant pathogens. Here we
show that PA has antifungal activity against some, but not all, of major
species of the human fungal pathogens from the genus Candida. Despite
of the demonstrated potency of PA against S. cerevisiae (Piotrowski
et al., 2015), our results demonstrated that PA did not have pan-Can-
dida activity, and is therefore unlikely to be useful as a pan-broad
spectrum antifungal agent. Although the mode of action of PA is not
understood in detail our results support the hypothesis that β-1,3-
glucan binding is important for PA action. This was underlined by ob-
servations that exogenous β-1,3-glucan attenuated PA inhibition – Most
likely by removing PA from solution. β-glucan synthesis involves
synthesis of β-1,3-glucan oligomers (nascent short polymers) by the
Rho1-dependent β-1,3-glucan synthases Fks1, Fks2 and Gsc1 using
UDP-glucose as the substrate (Douglas et al., 2001). The nascent poly-
saccharide matures into a β-glucan triple helix matures and subse-
quently undergoes structural modifications and crosslinking via a
number of transglycosidase and glucan modifying enzymes such as
Phr1, Phr2, the Chr family, Pga4, Pga5, Xog1, Eng1, Bgl2, and Kre62
(González et al., 1997; Plaine et al., 2008; Arroyo et al., 2016;
Aimanianda et al., 2017). Our results showed that the β-1,3-glucan
synthase activity in in vitro membrane preparations was inhibited to a
similar extent by PA in both C. albicans and S. cerevisiae (Fig. 1), sug-
gesting that effect of PA may not influence Fks1 catalytic activity di-
rectly and that differences in sensitivity to PA may be dependent on
access of this plant metabolite to β-1,3-glucan in the cytosol. Further-
more, mutants lacking XOG1, SMI1, KRE62, PGA4 or PAG5, which are
all involved in β-1,3-glucan synthesis, were not altered in PA sensitivity
(Suppl. Fig. 1). NMR analysis has demonstrated that the β-glucan of C.
albicans hyphal cell walls is a cyclic glucan different from the linear
glucans found in yeast cells (Kruppa et al., 2011; Lowman et al., 2014).
Although it is unclear where the exact binding site of PA, it is possible
that structure of β-1,3-glucan is important for the ability of nascent β-
1,3-glucan to mature and that PA binding to this polysaccharide com-
promises its structural integrity in an analogous way to Calcofluor
White binds to, and destabilises, β-1,4-linked N-acetylglucosamine of
chitin. However, because PA binds directly to β-glucan rather than the
Fks1 protein, it is possible that the Fks domain we have highlighted that
correlates with PA sensitivity is involved in β-glucan binding – The
product of Fks1 activity. In this model, for PA to efficiently inhibit β-
glucan synthesis, binding to this polysaccharide may occur immediately
after the nascent polysaccharide is formed. This binding may in turn
compromise β-glucan fibril maturation and ultimately its physical
strength.
We showed that point mutations in Candida Fks1 impacted
Fig. 4. (continued)
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differentially on PA and CSF susceptibility and that the transmembrane
topology that was determined in silico the position of the predicted
catalytic domain of Fks1 correlated with PA sensitivity. In S. cerevisiae,
the Fks1 protein is predicted to have 18 transmembrane helixes (TMHs)
(Johnson and Edlind, 2012). The central domain (residues ∼715–1300)
is highly conserved and required for enzyme function, leading to the
hypothesis that it may be associated with UDP-glucose binding and
catalysis (Johnson and Edlind, 2012). Computational predictions of
topographical models of this domain suggested that its localisation in
the plasma membrane may be species-dependent and that it may have
either an intracellular or extracellular localisation. Our data, and that
published previously, suggest that PA binds β-1,3 glucan directly and
that this event cause the polysaccharide instability leading to cell wall
damage. High PA sensitivity correlated with a theoretical predicted
intracellular location of this central domain – A hypothesis that remains
to be tested experimentally. We hypothesize that if PA binding is in-
tracellular it may immediately bind nascent β-glucan leading to more
profound perturbation of the structural properties of this structural
polysaccharide. Therefore, PA activity may be based on its ability to
directly interact with β-glucan rather than its direct effect on β-1,3-
glucan synthesis. However, the marked difference in the sensitivity of
medically important species to PA suggests that it may have limited
application as a lead compound informing new therapeutic strategies in
medical mycology.
The structural integrity of the cell wall is monitored by membrane
sensors that feed into the PKC/Mkc1 pathway and Hog1 and Ca2+/
calcineurin pathways (Munro et al., 2007). In C. albicans, PA did not
activate the PKC/Mkc1 cell wall salvage pathway that would be nor-
mally associated with upregulation of the chitin content and cell wall
remodelling in the cell wall (Figs. 3 and 4). Deletion of MKC1 in C.
albicans did not impact on the PA sensitivity compared to the wild type
control (Suppl. Fig. 1), although other genes involved in the PKC/Mkc1
pathway were not tested. In a previous study (Piotrowski et al., 2015),
S. cerevisiae mutants including rom2Δ, pkc1Δ, and bck1Δ involved in the
PKC pathway showed significantly increased sensitivity to PA. Deletion
of NBP2 (encoding the Hog1-negative regulator) and PTS1 (encoding a
protein phosphatase) resulted in increased resistance to PA. Further-
more, S. cerevisiae Sur1 and Csg2, which are involved in mannosyli-
nositol phosphorylceramide synthesis, activate the PKC pathway and
are resistant to PA when the cognate genes are deleted. It is however
possible that PA treatment could stimulate cell wall remodelling by via
PKC/Mkc1 independent mechanisms (Santiago et al., 2010).
The Ca2+/calcineurin pathway is also important for cell wall re-
modelling and stress responses to caspofungin (Bader et al., 2006;
Munro et al., 2007; Walker et al., 2008; Singh et al., 2009; Kaneko
et al., 2010; Lafayette et al., 2010). We showed here that deletion of
CNA1 or CNB1 increased the CSF sensitivity in C. albicans. The chitin
up-regulation response to caspofungin in C. albicans is also calcineurin-
dependent (Walker et al., 2008). Previously a screen of S. cerevisiae
Fig. 5. PA susceptibility of C. albicans cell wall as-
sociated mutants. [A] PA sensitivity of C. albicans
mutants lacking genes encoding the calcineurin sub-
units (cna1Δ, and cnb1Δ) was measured relative to
the control strains SC5314 and NGY152. * p < 0.05
compared to the controls. Error bars= SEM (n > 3).
[B] MIC sensitivity of PA against to strains containing
a point mutation in Fks1 or the heterozygous mutant
FKS1/fks1Δ was shown as percentage of growth the
DMSO control. White bars= 250 µg/ml; grey
bars= 500 µg/ml; black bars= 1000 µg/ml PA.
Error bars= SEM (n > 3),* p < 0.05 in comparison
to 100% growth of each strains, #p < 0.05 in com-
parison to SC5314. 2way ANOVA test.
Table 1
C. albicans containing an amino acid substitution in Fks1 Hotspot1.
Strain PA IC50 CSF IC50 Fks1 Hotspot1
μg/ml μg/ml Position Sequence
Reference SC5314 >1000 0.032 WT FLTLSLRDP
Clinical strains DPL12 >1000 0.545 F641S SLTLSLRDP
DPL1008 767 3.500 S645P FLTLPLRDP
DPL1012 >1000 0.340 D648Y FLTLSLRYP
DPL1013 >1000 0.600 P649H FLTLSLRDH
Lab strains NR3 515 2.300 S645Y FLTLYLRDP
fks1 S634 >1000 1.300 S645S/P FLTL(S/P)LRDP
fks1 S645P 590 3.700 S645P FLTLPLRDP
FKS1/fks1Δ >1000 0.016 WT/Δ FLTLSLRDP
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Fig. 6. PA susceptibility of Candida species. Ten Candida species plus S. cerevisiae were tested for their relative PA susceptibility. Strains in bold are the reference
strain for each species. The inhibitory concentrations (IC) at 50% and 10% growth were determined by analysing a locally weighted scatterplot smoothing (LOWESS)
method.
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mutants did not reveal a role for the Ca2+/calcineurin pathway in de-
termining PA sensitivity (Piotrowski et al., 2015). In contrast we
showed in C. albicans that cna1Δ and cnb1Δ were hypersensitive to PA
(Fig. 5A).
The accumulation of point mutations in one of three hot spot re-
gions of Fks1 has been shown to confer echinocandin resistance
(Garcia-Effron et al., 2009a; Garcia-Effron et al., 2010; Perlin, 2011;
Arendrup et al., 2014; Perlin, 2015b; Kolaczkowska et al., 2016). In
addition, inherent caspofungin or micafungin sensitivity is known to be
variable among Candida species independent of the presence of Fks1
point mutations (Walker et al., 2013a,b; Arendrup et al., 2014; Perlin
et al., 2015; Wanjare et al., 2016). We demonstrate that, PA sensitivity
also differed between Candida strains. Cell wall chitin can compensate
for β-glucan damage (Walker et al., 2008; Ben-Ami et al., 2011), but
again there was no observed correlation between chitin content and PA
sensitivity. In addition, our data demonstrated that β-1,3-glucan con-
tents of Candida species varied significantly (Fig. 7), however, PA
sensitivity did not correlate with gross glucan content of different
Candida species.
In summary, our data suggest that PA and echinocandins inhibit β-
1,3-glucan synthesis by different mechanisms and that the extent of PA
inhibition is fungal species-specific. It is likely that PA does not directly
interfere with the catalytic process of forming β-1,3-glucan at the cy-
toplasmic face of the membrane, but rather interferes with β-1,3-glucan
maturation leading to a weaker cell wall. The variability in the ability of
PA to inhibit a range of Candida pathogens limits its potential for
development as a novel antifungal agent.
Materials and Methods
Strains, media, and chemicals
The fungal strains used in this study are listed in Suppl. Table 1. All
strains of Candida species and S. cerevisiae were grown on an YPD agar
plate (1% yeast extract, 2% peptone, 2% glucose, and 2% agar). For
overnight cultures, single colonies from the agar plates were inoculated
in either YPD or NGY broth (0.1% yeast extract, 0.1% neopeptone, and
0.4% glucose), and incubated at 30 °C with shaking at 200 rpm. Uridine
(25 μg/ml) was supplemented in the medium for uridine auxotrophic
mutants. CSF was obtained from the Aberdeen Royal Infirmary. Echi-
nocandin B was generous gift from Osamu Kondo (Chugai Pharma-
ceutical Co., Tokyo, Japan).
Antifungal susceptibility test
The antifungal susceptibility of PA against various Candida species
and S. cerevisiae strains was determined according to CLSI M27-A3
guidelines in using modified RPMI-1640 (2mM L-glutamine, 0.2M
MOPS, 2% glucose (w/v), pH7.2) as described previously (Lee et al.,
2012). Briefly, fungal cells were grown in NGY at 30 °C with shaking at
200 rpm overnight to reach a stationary phase. Overnight cultures were
washed with distilled water and then inoculated in RPMI-1640 (with/
Fig. 7. Cell wall glucan contents in different Candida
species and S. cerevisiae. [A and B] MIC of PA was
calculated with exogenous β-1,3-glucan (βGlu) at
0.25mg/ml or 0.5mg/ml. C. albicans wild type [i]
and S. cerevisiae [ii] were treated with PA only or PA
with βGlu. Results are expressed as percentage of
growth relative to the control (DMSO). Error
bars= SEM (n > 3). * p < 0.05. 2way ANOVA test.
[B] Correlation between glucan content and PA IC50
values of different Candida species. Cells were grown
exponentially for 6 h in YPD and washed with PBS.
Cells were then fixed with 4% formaldehyde. Aniline
Blue (25 µg/ml) was used to stain cell wall β-glucan.
Fluorescence levels of individual cells (1× 104) were
measured by FACS. The IC values were calculated
using LOWESS analysis based on the sensitivity assay.
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without drugs) to reach approximately up to 5×104 cells/ml, and in-
cubated at 37 °C for 24 h in a static incubator. PA concentrations ranged
from 0 to 1000 μg/ml, and CSF concentrations from 0 to 16 µg/ml. The
glucan extracted from Euglena gracilis (Sigma, 89862-1G-F) was dis-
solved/gelatinised in DMSO, and used in some experiments in which β-
glucan was provided exogenously. After 24 h incubation in microtitre
plates, the optical density of wells was measured using a VERSAmax
plate reader (Molecular Devices, USA) at 405 nm. For the post-sensi-
tivity assays of cell viability, 2.5 μl samples were taken from the sen-
sitivity assay microtitre plates and were spotted on a fresh YPD and
incubated at 30 °C overnight. The inhibitory concentration of MIC
plates at 50% cell survival (IC50) or a 10% cell survival (IC90) was
calculated from LOWESS curves using GraphPad Prims 5 (v5.04).
Combinatorial sensitivity assays
Combinatorial inhibition assays were performed to investigate sy-
nergistic effect of PA with echinocandins. Growth conditions were
identical to that used in antifungal susceptibility tests described above.
A 12×8- or 8× 8-dose-defined matrix was used in 96-well plates
containing PA (0.98 to 1000 μg/ml) in combination with either CSF
(0.032–16 μg/ml), NKZ (0.625–40 μM), or CFW (0.2–200 μg/ml). After
incubating for 24 h at 37 °C, the final OD at 405 nm was determined.
Results are presented as a heatmaps or a bar charts of the percentage of
growth inhibition observed. Synergistic effects were calculated as de-
scribed (Piotrowski et al., 2015) using the formula E=A×B/C (where
E is the expected percentage of inhibited growth; A is the percentage
growth of when compound A (PA) is applied alone; B is the percentage
growth when compound B (CSF) is applied alone; C is the percentage
growth DMSO control. Sub-MIC or IC50 concentrations of PA or cas-
pofungin were used for analysis of synergistic effects. Combinations of
1000, 500 and 62.5 µg/ml PA and 0.062, 2, and 0.25 µg/ml CSF for
SC5314, NR3 and S288C respectively were used. A combination of
500 µg/ml PA and 25 µg/ml CFW or 40 µM NKZ were used for SC5314.
Semi-quantification of cell wall chitin
Cells treated with either PA or CSF were fixed with 10% neutral
buffered formalin and stained with 25 µg/ml CFW to visualise cell wall
chitin. Samples were observed by differential interference contrast
(DIC) microscopy as described in the previous study (Walker et al.,
2008; Lee et al., 2012) using a Zeiss Axioplan 2 microscope to observe
samples. The Openlab software (Openlab v 5.02) was used to take
images of samples and the CFW fluorescent intensity of individual cells
was measured using ImageJ (v1.47).
Mannoprotein and glucan staining
β-1,3-glucan was stained with Aniline Blue (016-21302; Wako
Chemicals). Mannoprotein was stained with Alexa594-ConA (C11253;
Life Technologies). β-1,3-glucan and mannoprotein were stained as
described previously (Piotrowski et al., 2015; Okada et al., 2014; Okada
and Ohya., 2016) with slight modification. Briefly, over-night cultured
yeast cells were cultured in YPD with PA (500 μg/ml for S288C and
SC5314 or 125 μg/ml for NR3) or with echinocandin B (4 μg/ml) at
30 °C. Then, cells were collected at 2 h (for echinocandin B) or 6 h (for
PA) after treatment and stained with Alexa594-ConA and Aniline Blue
without fixation. Cells mounted on a glass slide were exposed to UV for
30 s to bleach out PA fluorescence before acquiring images.
For fluorescence-activated cell sorting, applied in flow cytometry
(FACS) analysis, cells were first grown in YPD at 30 °C for 6 h. Cells
were washed twice with PBS, and fixed in 3.7% formaldehyde. Fixed
cells were diluted in PBS to reach 1× 106 cells/ml, 0.5 mM EDTA was
added, and samples were sonicated in a water bath for up to 10min to
disrupt cell clumps. Aniline Blue (25 μg/ml) was added immediately
before FACS analysis. Unstained controls were used to establish the
basal level of fluorescence. A total of 10,000 cells per sample were
analysed by FACS according to BD Fontesa manufacturer’s guidelines
(BD Biosciences). Data obtained by the BD FACSDiva software were
transferred and analysed by FlowJo (v10.02) to semi-quantify the
fluorescence intensity representing β-glucan contents.
In vitro β-1,3-glucan synthase activity
To prepare membrane microsomal fractions, cells were grown at
30 °C to a density of 2–4× 107 cells/ml. The following procedures were
carried out at 4 °C. Cells were harvested, washed with 1mM EDTA, and
disrupted by vortexing 4 times for 2min each with 5ml of glass beads
in 10ml of breaking solution containing 0.5M NaCl, 1 mM EDTA with
1mM phenylmethylsulfonyl fluoride. After centrifugation at 1,200× g
for 5min, the supernatant was collected and transferred to 33 PC tubes
(Hitachi, Japan). Pellets were resuspended in breaking solution, and
centrifuged at 1,200× g for 1min. The supernatant was also trans-
ferred to new 33 PC tubes. Membrane fractions in 33 PC tubes were
collected by centrifugation at 100,000×g for 30min in an RP70T-203
rotor (Hitachi) with Himac CP 65β (Hitachi). The resultant microsomal
membrane pellet was suspended in membrane buffer containing 50mM
Tris-HCl, pH 7.5, 10mM EDTA, 1mM β-mercaptoethanol, and 33%
glycerol, homogenized, and stored at− 80 °C to obtain membrane
mixture.
β-1,3-glucan synthase activity was measured as described pre-
viously (Piotrowski et al., 2015) with slight modifications. First, a re-
action mixture was prepared containing 25mM Tris·HCl pH 7.5, 25mM
potassium fluoride, 0.5mM EDTA, 0.4% Brij-35, and 0.2 mM UDP-Glc
(with 57 Bq UDP-[Glucose-14C]; NEC403; PerkinElmer). Brij-35 was
used for membrane solubilisation was included in the reaction solutions
for assays of C. albicans β-1,3-glucan synthase activity (Frost et al.,
1994). Membrane fractions containing 50 μg total protein was included
in the membrane mixture containing 2.0 μM GTP-γ-S and different
concentrations of PA. The membrane fractions (20 μl) were added to
80 μl of the reaction mixture, incubated at 30 °C for 30min, and
stopped by the addition of ethanol. Trapping β-1,3-glucan polymer
from the sample was collected by membrane filtration (cellulose ester
membranes; 0.2 μm in pore size; ADVANTEC), and washed one time
with 1ml distilled water. Membrane filters were dried at room tem-
perature for 2 h, and measured the radioactivity by a scintillation
counter (LSC-6100; Aloka) with 2.5 ml scintillation mixture (Econo-
fluor-2; PerkinElmer). The half maximal inhibitory concentration
(IC50GS) was calculated after fitting with Gamlss beta in the R Gamlss
package.
High Pressure, freeze substitution transmission electron microscopy (HPF-
TEM)
HPF-TEM was performed as described previously (Hall et al., 2013)
with some modification. C. albicans SC5314 and S. cerevisiae S288C
were grown in YPD at 30 °C overnight. The following day, overnight
cultures were diluted in a fresh YPD medium to an OD600 of 0.2 and
incubated at 30 °C for 1 h. Then cells were treated for further 6 h with
DMSO (0.5% for SC5314 or 0.1% for S288C) or PA (500 μg/ml for
SC5314 or 100 μg/ml for S288C). After incubation, cells were collected
and washed with mQ-water. Cells were freeze-substituted by using a
Leica EM AFS2 automatic freeze substitution system (Leica Micro-sys-
tems). Further steps were carried out according to the previous study
(Hall et al., 2013). To quantify the length of the inner (chitin+ glucan)
and outer (mannan fibrils) layers, images were transported into ImageJ
(v1.47), and 5–12 cells were randomly selected, and 5–45 measure-
ments made from the different angles of each cell. The results present as
a mean (nm) with SEM.
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Mkc1 phosphorylation analysis by western analysis
Western analysis was performed using methods described pre-
viously with modifications (Munro et al., 2007). Overnight cultures of
C. albicans wild type, C. albicans NR3 (Fks1-S645Y), and S. cerevisiae
were diluted in fresh YPD and then incubated for 4 h at 30 °C with
shaking until they reached mid-log phase. Cells were then treated for
10min with appropriate treatments, with equivalent non-treated cells
used as a control. After treatments, cells were collected, and their total
protein complement was extracted.
Proteins (15 µg) were separated by SDS–PAGE (polyacrylamide gel)
electrophoresis; NuPAGE®Novex Bis-Tris 4–12% Precast gels
(Invitrogen). Blotting was performed according to the manufacturer’s
instructions. A mix of the SeeBlue® Plus2 Pre-stained (Invitrogen) and
MagicMarkTM standards (Invitrogen) were loaded as markers. After
blotting, separated proteins were transferred onto PVDF membranes
which were rinsed with PBS and blocked in PBS-T 10% BSA (0.1%
Tween-20, 10% BSA in PBS) for 30min at RT. Membranes were then
incubated overnight at 4 °C with Phospho-p44/42 MAP Kinase
(Thr202/Tyr204) Antibody (Cell Signalling Technology) in PBS-T 5%
BSA (0.1% Tween-20, 5% BSA in PBS). For secondary antibody
staining, the membranes were incubated at RT for 60min in PBS-T 5%
BSA containing an anti-rabbit IgG, HRP-linked Antibody (Cell
Signalling Technology). Signals were enhanced by SuperSignal® West
Femto Maximun Sensitivity Substrate (Thermo Scientific) according to
the manufacturer’s instructions. Chemiluminescence signal detection
was performed using the Fusion image acquisition system v15.15
(PeQLab Biotechnologie GmbH, Germany).
Creating a mutant containing Fks1 amino acid substitution
Amino acid substitutions in Fks1 (orf19.2929/C1_02420C) were
introduced in C. albicans, using the CRISPR-Cas9 system according to a
previous study with modifications (Vyas et al., 2015). A single guide
RNA was generated using primers of Fks1sgRNA-Fwd and Fks1sgRNA-
Rev (Suppl. Table 2). The single guide RNA targeting the FKS1 locus
was ligated into the plasmid, pV1200. Positive clones were selected on
LB plate containing 100 μg/ml ampicillin and 50 μg/ml nourseothricin.
Constructs were confirmed by sequencing. Before, transformation, the
plasmid pV1200+ FKS1sgRNA (2–3 µg) for the Cas9 system was di-
gested with KpnI and SacI. The repair template was created using oligos
of FKS1rt_Fwd and S645P_Rev. Repair templates (10 μg) were purified
and transformed along with linearized pV1200_FKS1sgRNA into C. al-
bicans SC5314. The repair templates contained the desired point mu-
tation (serine to proline at 645), and a silencing mutation at 635 (TTG,
Leucine to TTA, Leucine) to prevent the Cas9 system repeatedly cutting
the NGG site. A positive colony was selected by plating on an YPD agar
200 μg/ml nourseothricin, and then grown on YPD agar containing
0.5 μg/ml caspofungin. All positive transformations were confirmed by
the DNA sequencing analysis as previously described (Lee et al., 2012).
To create the dysfunctional fks1 mutant, the repair template was pro-
duced by using oligos of FKS1rt_Fwd and fks1del_Rev. The repair tem-
plate was purified and transformed along with linearized
pV1200_FKS1sgRNA into C. albicans SC5314. Positive transformants
were selected on an YPD with 200 μg/ml nourseothricin. All mutants
were screened by Sanger sequencing with primers of Fks1_HS1_F and _R
(Genewiz UK; https://www.genewiz.com/).
Computational analysis of Fks1 or β-1,3-glucan synthase homologue
proteins
The amino acid sequences of Fks1 or homologues in all reference
strains was obtained from the Candida genome database (http://
www.candidagenome.org), the Saccharomyces genome database
(http://www.yeastgenome.org) or from the NCBI (http://
www.ncbi.nlm.nih.gov) (Table 2). The multiple protein sequence
alignment of homologue Fks1s in Candida species was performed by
using the web-based analysis tool, MUSCLE (http://www.ebi.ac.uk/
Tools/msa/muscle) using S. cerevisiae Fks1 as the comparator sequence.
The phylogenetic tree of Fks1 was created after MUSCLE analysis, and
then re-generated as an unrooted phylogenetic tree, using TreeDyn
198.3 (http://www.phylogeny.fr/). The transmembrane topology pre-
diction of homologue Fks1 was performed via the web-tool, Phobius
(http://phobius.sbc.su.se/index.html).
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Table 2
Analysis of Fks1 β-1,3-glucan conserved central domain in Candida species.
Species Strain
name
Protein sequence info. Protein
length
Chromosome info. Source Amino acid position (putative β-1,3-
glucan synthase components)
Domain facing
C. albicans SC5314 C1_02420cp_a 1897 Chr1 CGD 701-1361 NON CYTOPLASMIC
C. glabrata CBS 138 Cagl0k01034gp 1863 ChrG CGD 685-1344 NON CYTOPLASMIC
C. dubliniensis CD36 Cd36_02270p 1897 Chr1 CGD 701-1361 NON CYTOPLASMIC
C. guilliermondii ATCC 6260 EDK37070 1882 Supercontig
CH408155
Ensemble Fungi 713-1295 CYTOPLASMIC
C. krusei ATCC 6258 AAY40291.2 1885 NA NCBI 715-1368 NON CYTOPLASMIC
C. orthopsilosis 90-125 CCG22470 1902 Chr2 EnsembleFungi 726-1310 CYTOPLASMIC
C. parapsilosis ATCC
22,019
Cpar2_106400p 1909 Chr1 CGD 733-1373 CYTOPLASMIC
C. tropicalis MYA-3404 EER31878 1280 Supercontig3.6 EnsembleFungi 86-746 NON CYTOPLASMIC
S. cerevisiae S288C YLR342W 1876 Chr XII SGD 720-1357 CYTOPLASMIC
CGD= Candida Geneome Database (http://www.candidagenome.org/).
EnsembleFungi= http://fungi.ensembl.org/index.html.
NCBI=National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/guide/).
SGD= Saccharomyces Genome Database (http://www.yeastgenome.org/).
Transmembrane domain analysis by using the web-based software, Phobius (http://phobius.sbc.su.se/).
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